Heather Cooper Ortner joins the International Myeloma Foundation as president & CEO

Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)

Amid deepening controversy, Vinay Prasad, FDA’s top clinician and scientist, and director of its Center for Biologics Evaluation and Research, will be leaving the agency.

March 13, 2026

Vol.52 No.10

By Claire Marie Porter

In Brief

Vivek Subbiah to lead Early Drug Development Program at Stanford Cancer Institute

Vivek Subbiah has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026.

March 13, 2026

Vol.52 No.10

In Brief

Lonny Yarmus named head of the Division of Subspecialty Medicine at MSK

Lonny Yarmus was appointed head of the Division of Subspecialty Medicine in the Department of Medicine at Memorial Sloan Kettering Cancer Center. A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation, Yarmus is widely known for his expertise in minimally invasive diagnostics and therapeutics, outcomes research, and multidisciplinary program development.

March 13, 2026

Vol.52 No.10

In Brief

GRAIL announces retirement of CEO Bob Ragusa, appoints President Josh Ofman as successor

GRAIL has announced that Bob Ragusa will retire as CEO, effective June 1.

March 13, 2026

Vol.52 No.10

Clinical Roundup

Positive phase III results announced from the SUCCESSOR-2 study of oral mezigdomide in r/r MM

Oral mezigdomide in combination with carfilzomib and dexamethasone demonstrated statistically significant and clinically meaningful improvement in progression-free survival versus carfilzomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma, according to positive interim phase III results from the SUCCESSOR-2 study.

March 13, 2026

Vol.52 No.10

In Brief

Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition

W. Kimryn Rathmell, CEO of the James Cancer Hospital and Solove Research Institute, has also been named director of The Ohio State University Comprehensive Cancer Center in place of former Director Raphael E. Pollock, who has stepped down from the position he had held since November 2017 to become OSUCCC director emeritus.

March 06, 2026

Vol.52 No.09

Heather Cooper Ortner joins the International Myeloma Foundation as president & CEO

YOU MAY BE INTERESTED IN

Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)

Vivek Subbiah to lead Early Drug Development Program at Stanford Cancer Institute

Lonny Yarmus named head of the Division of Subspecialty Medicine at MSK

GRAIL announces retirement of CEO Bob Ragusa, appoints President Josh Ofman as successor

Positive phase III results announced from the SUCCESSOR-2 study of oral mezigdomide in r/r MM

Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition

Renew today!

Subscriber content

Never miss an issue!

Login